Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.
Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, Phillips PP, Spears MR, Rowley S, Kaplan R, James ND, Maughan T, Paton N, Royston PJ. Parmar MK, et al. Among authors: langley re. Clin Trials. 2017 Oct;14(5):451-461. doi: 10.1177/1740774517725697. Epub 2017 Aug 22. Clin Trials. 2017. PMID: 28830236 Free PMC article.
Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study.
Mason M, Warde P, Sydes M, Cowan R, James N, Kirkbride P, Langley R, Latham J, Moynihan C, Anderson J, Millet J, Nutall J, Moffat L, Parulekar W, Parmar M; National Cancer Institute of Canada Clinical Trials Group PR3/; Medical Research Council PR07 Trial Management Group. Mason M, et al. Clin Oncol (R Coll Radiol). 2005 Jun;17(4):217-8. doi: 10.1016/j.clon.2005.02.013. Clin Oncol (R Coll Radiol). 2005. PMID: 15997913 No abstract available.
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).
Mason MD, Sydes MR, Glaholm J, Langley RE, Huddart RA, Sokal M, Stott M, Robinson AC, James ND, Parmar MK, Dearnaley DP; Medical Research Council PR04 Collaborators. Mason MD, et al. Among authors: langley re. J Natl Cancer Inst. 2007 May 16;99(10):765-76. doi: 10.1093/jnci/djk178. J Natl Cancer Inst. 2007. PMID: 17505072 Clinical Trial.
Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.
Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, Pollock P, Kockelbergh R, Lalani el-N, Dearnaley D, Parmar M, Abel PD. Langley RE, et al. BJU Int. 2008 Aug;102(4):442-5. doi: 10.1111/j.1464-410X.2008.07583.x. Epub 2008 Apr 16. BJU Int. 2008. PMID: 18422771 Free PMC article. Clinical Trial.
Speeding up the evaluation of new agents in cancer.
Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P. Parmar MK, et al. J Natl Cancer Inst. 2008 Sep 3;100(17):1204-14. doi: 10.1093/jnci/djn267. Epub 2008 Aug 26. J Natl Cancer Inst. 2008. PMID: 18728279 Free PMC article.
Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner. J Urol 2010;184:1316-1321.
Langley RE, Cafferty FH, Pollock PA, Price P, Abel PD. Langley RE, et al. J Urol. 2011 Jun;185(6):2430-1; author reply 2431-2. doi: 10.1016/j.juro.2011.02.036. Epub 2011 Apr 22. J Urol. 2011. PMID: 21513954 No abstract available.
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE; FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Seymour MT, et al. Among authors: langley re. Lancet. 2011 May 21;377(9779):1749-59. doi: 10.1016/S0140-6736(11)60399-1. Epub 2011 May 11. Lancet. 2011. PMID: 21570111 Free PMC article. Clinical Trial.
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.
Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi LY, Domingo E, Smillie C, Henrion M, Frampton M, Martin L, Grimes G, Gorman M, Semple C, Ma YP, Barclay E, Prendergast J, Cazier JB, Olver B, Penegar S, Lubbe S, Chander I, Carvajal-Carmona LG, Ballereau S, Lloyd A, Vijayakrishnan J, Zgaga L, Rudan I, Theodoratou E; Colorectal Tumour Gene Identification (CORGI) Consortium; Starr JM, Deary I, Kirac I, Kovacević D, Aaltonen LA, Renkonen-Sinisalo L, Mecklin JP, Matsuda K, Nakamura Y, Okada Y, Gallinger S, Duggan DJ, Conti D, Newcomb P, Hopper J, Jenkins MA, Schumacher F, Casey G, Easton D, Shah M, Pharoah P, Lindblom A, Liu T; Swedish Low-Risk Colorectal Cancer Study Group; Smith CG, West H, Cheadle JP; COIN Collaborative Group; Midgley R, Kerr DJ, Campbell H, Tomlinson IP, Houlston RS. Dunlop MG, et al. Nat Genet. 2012 May 27;44(7):770-6. doi: 10.1038/ng.2293. Nat Genet. 2012. PMID: 22634755 Free PMC article.
127 results